KRRONCMHealthcare·Biotechnology#317 in industry

Korro Bio, Inc.

Reports in 9d· 2026-05-06

+19.6% · 90d

$12.84

-0.05 (-0.35%)

After-Hours $12.84(+0.00)

News

No News Yet

Press releases and SEC filings for KRRO will appear here as they are published.

Check back later for updates

Key Data

Market Cap$185.2M

Open$12.86

Prev Close$12.88

Day Range$12.77 – $13.40

52W Range$5.20 – $55.89

Volume59,420

P/E (TTM)—

EPS$-12.48

Dividend Yield—

Beta2.43

Revenue Growth-43.10%

Price Target$20.00(+55.8%)

Next Earnings2026-05-06(9d)

Analyst Ratings

Strong Buy9 analysts

Buy 7Hold 2Sell 0

About

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Healthcare · Biotechnology

58 employees

www.korrobio.com